Adapting Clinical Practice to a Rapidly Changing Therapeutic Landscape in Multiple Myeloma

Join us for this live symposium featuring discussion of patient case studies and key clinical trial data by renowned clinical experts providing their perspectives on recent advances in the treatment of multiple myeloma.

You will have multiple opportunities to interact with faculty through patient case scenarios and audience Q&A sessions.

Sign up now! Registration is complimentary.

Friday Satellite Symposium on Adapting Clinical Practice to a Rapidly Changing Therapeutic Landscape in Multiple Myeloma, preceding the 63rd ASH Annual Meeting and Exposition.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

Welcome and Introduction

Patient Case Studies with short didactic and panel discussions

  • Case Discussion 1: Evidence for Treating High-Risk Smoldering MM
  • Case Discussion 2: Current Therapeutic Strategies for Newly Diagnosed MM
  • Case Discussion 3: Tailoring Management for Patients With MM in First Relapse
  • Case Discussion 4: Expert Guidance for Managing Heavily Treated Disease
  • Case Discussion 5: Evolving Role for BCMA-Targeted Therapies

Future Directions in MM Care: Agents That Will Soon Change Practice

New 2022 Treatment Algorithm for MM

Final Thoughts

Faculty

Program Director
Brian G.M. Durie, MD

Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Faculty
Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California

Faculty
Philippe Moreau, MD

Professor of Clinical Hematology
Head,
Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

Faculty
S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Faculty
Jesús F. San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain

Goal Statement
The goal of this activity is to improve learners’ knowledge of and competence in applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Initiate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnosis, staging criteria, and risk factors
  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data as well as risk assessment, comorbidities, and patient age/fitness and preferences
  • Appraise the efficacy and safety evidence of novel combination therapeutic regimens for patients with multiple myeloma
  • Select optimal therapies for patients with heavily pretreated relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as response to and tolerance of previous therapies
  • Identify patients with relapsed/refractory multiple myeloma who would be eligible for enrollment on key ongoing clinical trials
  • Manage adverse events related to newer therapies used in the treatment of multiple myeloma to ensure optimal clinical benefit from treatment

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.